Sky View Investment Advisors, LLC Uni Qure N.V. Transaction History

Sky View Investment Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$11.12 - $22.2 $6,293 - $12,565	-566 Reduced 67.87%	268 $3,000
Q4 2022 Feb 16, 2023	BUY	$18.12 - $27.32 $1,286 - $1,939	71 Added 9.31%	834 $19,000
Q3 2022 Nov 16, 2022	SELL	$16.98 - $25.54 $1,205 - $1,813	-71 Reduced 8.51%	763 $14,000
Q1 2022 May 17, 2022	BUY	$14.54 - $21.5 $10,919 - $16,146	751 Added 904.82%	834 $15,000
Q4 2021 Feb 18, 2022	BUY	$20.24 - $36.01 $1,679 - $2,988	83 New	83 $18,000
Q3 2021 Nov 16, 2021	SELL	$26.01 - $38.22 $10,273 - $15,096	-395 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$29.24 - $42.03 $10,204 - $14,668	349 Added 758.7%	395 $13,000
Q4 2020 Mar 02, 2021	BUY	$35.35 - $50.67 $1,626 - $2,330	46 New	46 $2,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Sky View Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Sky View Investment Advisors, LLC with notifications on news.